SYRE
Spyre Therapeutics, Inc. · Healthcare
47.58
2.70%(-1.32)
Market Closed52.32
9.96%(+4.74)
After HoursLast Updated: — ET
52W L: $10.9152W H: $51.06
$49.51
CHG+9.36 (+23.31%)
H$51.59
L$38.41
VOL12M
SYRE (1h)
Spyre Therapeutics, Inc. · Healthcare
Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report) CFO Scott Burrows sold 7,500 shares of the stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $49.34, for a total transaction of $370,050.00. Following the transaction, the chief financial officer owned 97,994 shares of the company's stock, valued
WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 70,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on April 1, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).
VR Adviser, LLC added 1,000,000 shares of Spyre Therapeutics; estimated trade size is $25.78 million (based on quarterly average pricing). The quarter-end value of the position increased by $75.73 million, reflecting both trading activity and share price appreciation.
Spyre Therapeutics, Inc. receives a Strong Buy rating, driven by positive phase 1 data and robust pipeline progress in IBD and rheumatic diseases. SPY001 demonstrated a half-life 4x greater than ENTYVIO, supporting quarterly or twice-yearly dosing for ulcerative colitis in the ongoing phase 2 SKYLINE trial. Accelerated recruitment in the phase 2 SKYWAY RA sub-study brings the anti-TL1A SPY072 data readout forward to Q3 2026, enhancing SYRE's near-term catalysts.
B Group Inc. increased its holdings in Spyre Therapeutics, Inc. (NASDAQ: SYRE) by 25.0% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 100,000 shares of the company's stock after buying an additional 20,000 shares during the period. Spyre Therapeutics comprises approximately 1.3% of B
Spyre Therapeutics, Inc. (SYRE) Presents at Leerink Global Healthcare Conference 2026 Transcript
Turtle Cameron
director, officer: Chief Executive Officer
12,344 SH @ $49.20
2026-04-01
Turtle Cameron
director, officer: Chief Executive Officer
2,656 SH @ $49.92
2026-04-01
Sloan Sheldon
officer: Chief Medical Officer
7,958 SH @ $21.66
2026-04-01
Sloan Sheldon
officer: Chief Medical Officer
7,958 SH @ $21.66
2026-04-01
Sloan Sheldon
officer: Chief Medical Officer
7,958 SH @ $50.00
2026-04-01
Burrows Scott L
officer: Chief Financial Officer
7,500 SH @ $14.50
2026-04-01
Burrows Scott L
officer: Chief Financial Officer
7,500 SH @ $14.50
2026-04-01
Burrows Scott L
officer: Chief Financial Officer
6,200 SH @ $49.21
2026-04-01